$9.5 M

USRM Mkt cap, 08-Oct-2018

$3.5 M

U.S. Stem Cell Revenue Q2, 2018
U.S. Stem Cell Gross profit (Q2, 2018)2.5 M
U.S. Stem Cell Gross profit margin (Q2, 2018), %69.7%
U.S. Stem Cell Net income (Q2, 2018)-1.4 M
U.S. Stem Cell EBIT (Q2, 2018)-832.6 K
U.S. Stem Cell Cash, 30-Jun-20181.7 M

U.S. Stem Cell Revenue

U.S. Stem Cell revenue was $5.52 m in FY, 2017

Embed Graph

U.S. Stem Cell Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

96.1k2.1m2.2m3.1m5.5m

Revenue growth, %

2040%7%41%

Cost of goods sold

30.8k844.9k973.0k972.0k1.9m

Gross profit

65.3k1.2m1.2m2.1m3.6m

Gross profit Margin, %

68%59%56%68%66%

R&D expense

627.0k66.4k10.0k919.06.6k

General and administrative expense

4.4m

Operating expense total

627.0k66.4k10.0k919.04.4m

Depreciation and amortization

6.6k

EBIT

(2.8m)(3.5m)(2.6m)(1.2m)(804.7k)

EBIT margin, %

(2947%)(172%)(119%)(38%)(15%)

Interest expense

1.4m1.6m1.7m1.2m642.1k

Pre tax profit

(3.1m)(2.3m)(1.6m)(2.1m)(3.5m)

Net Income

(3.1m)(2.3m)(1.6m)(2.1m)(3.5m)

Quarterly

USDQ1, 2018Q2, 2018

Revenue

1.7m3.5m

Cost of goods sold

503.8k1.1m

Gross profit

1.2m2.5m

Gross profit Margin, %

71%70%

R&D expense

1.3k3.9k

General and administrative expense

1.2m3.3m

Operating expense total

1.2m3.3m

Depreciation and amortization

524.0524.0

EBIT

(9.3k)(832.6k)

EBIT margin, %

(1%)(24%)

Interest expense

242.4k683.4k

Pre tax profit

(139.2k)(1.4m)

Net Income

(139.2k)(1.4m)

U.S. Stem Cell Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2017

Cash

46.2k36.7k58.4k986.8k

Accounts Receivable

43.0k

Inventories

70.4k

Current Assets

66.9k141.3k115.6k1.1m

PP&E

9.1k12.7k14.2k449.7k

Total Assets

86.1k204.8k229.1k1.6m

Accounts Payable

10.2k

Current Liabilities

13.4m11.1m5.7m6.5m

Total Liabilities

8.7m

Additional Paid-in Capital

103.8m108.9m114.6m120.2m

Retained Earnings

(120.4m)(122.1m)(127.6m)

Total Equity

(13.7m)(10.9m)(7.7m)(7.1m)

Financial Leverage

0 x0 x0 x-0.2 x

Quarterly

USDQ1, 2018Q2, 2018

Cash

1.7m1.7m

Accounts Receivable

75.9k47.4k

Inventories

76.7k66.1k

Current Assets

1.9m1.8m

PP&E

397.6k345.9k

Total Assets

2.4m2.2m

Accounts Payable

10.2k10.2k

Current Liabilities

6.7m7.2m

Total Liabilities

8.8m9.2m

Additional Paid-in Capital

121.0m121.6m

Retained Earnings

(127.8m)(129.0m)

Total Equity

(6.4m)(7.0m)

Financial Leverage

-0.4 x-0.3 x

U.S. Stem Cell Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(3.1m)(2.3m)(1.6m)(2.1m)(3.5m)

Depreciation and Amortization

2.2k4.5k5.3k5.8k178.7k

Accounts Receivable

(43.7k)

Inventories

(28.1k)

Accounts Payable

469.2k

Cash From Operating Activities

(1.9m)(1.1m)(844.7k)1.2m

Purchases of PP&E

(1.2k)

Cash From Investing Activities

(9.4k)(57.8k)(234.0k)723.8k

Cash From Financing Activities

(1.2m)

Interest Paid

521.7k429.6k321.8k255.9k

U.S. Stem Cell Ratios

USDY, 2018

Financial Leverage

-0.3 x
Report incorrect company information